90.73
-1.46%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $4.95bn
- Last close × shares
- Volume
- 536.7k
- Shares, 20 Nov 2026
About LivaNova
From its filings with the US Securities and Exchange Commission
LivaNova is based in Gloucester and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker LIVN. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.39bn and a net loss of $242.5m. At that date it held total assets of $2.61bn and shareholders' equity of $1.20bn.
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. “Other” includes non-allocated corporate expenses and the non-cannula results of the Company’s former ACS segment, which was wound down during 2024.
LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products. In particular, the Cardiopulmonary segment includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during CPB procedures.
CPB is frequently utilized in various heart-related medical procedures and allows surgical teams to oxygenate and circulate a patient’s blood, providing the necessary conditions for the surgeon to operate on the heart. Medical procedures most commonly requiring CPB include traditional coronary artery bypass grafting and valve surgeries. LivaNova’s products enable CPB for neonatal, pediatric, and adult patients.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2017
- Cardiac Surgery [Member] $635.5m · 62.8%
- Neuromodulation [Member] $375.0m · 37.0%
Latest on LivaNova
Our reporting
Next results
Due on 24 Feb 2027. Analysts expect earnings of 0.98 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is LivaNova's ticker?
LivaNova trades as LIVN on its US listing, under ISIN GB00BYMT0J19.
What was LivaNova's last closing price?
90.73 on 20 Nov 2026. The figure is in USD and is never converted.
When does LivaNova next report results?
Results are expected on 24 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.